Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Sep;202(3):533-538.
doi: 10.1097/JU.0000000000000295. Epub 2019 Aug 8.

Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019

Thomas M Pisansky  1   2 , Ian M Thompson  1   2 , Richard K Valicenti  1   2 , Anthony V D'Amico  1   2 , Shalini Selvarajah  1   2
Affiliations
Practice Guideline

Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019

Thomas M Pisansky et al. J Urol. 2019 Sep.

Abstract

Purpose: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians.

Materials and methods: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy.

Results: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found.

Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

Keywords: prostatic neoplasms; radiation; salvage therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Meta-analysis of biochemical recurrence data from SWOG 8794, EORTC 22911, and ARO 96–02
See this image and copyright information in PMC

References

    1. American Cancer Society: Key statistics for prostate cancer. 2018; https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html; downloaded 9/25/2018.
    1. Amling CL, Blute ML, Bergstralh EJ et al.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101. - PubMed
    1. Chun FK, Graefen M, Zacharias M et al.: Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006; 24: 273. - PubMed
    1. Han M, Partin AW, Pound CR et al.: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555. - PubMed
    1. Bianco FJ Jr., Scardino PT and Eastham JA: Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 2005; 66: 83. - PubMed

Publication types

MeSH terms

Substances